phase 1 results

Safety and blood levels of GSK's exon-skipping drug were evaluated in boys with Duchenne MD who were no longer walking and had specific dystrophin mutations

posted on November 2, 2012 - 5:15pm
Update (Sept. 19, 2013): This story was updated to reflect the availability of a scientific paper detailing the trial results; it was published online Sept.

New content is being added every day. Please check back again.